EMAS
European Male Ageing Study (Wu et al., NEJM 2010)
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
0 human trials, about 1 studies, ~3,369 participants men aged 40-79, 8 European centers. The written rationale for this grade is still being prepared.
- FDA
- Observational multicenter cohort (not a drug study)
Reference only. Not medical advice.
What can go wrong
Not an intervention; its clinical importance is protective - by requiring both specific symptoms and confirmed low hormone levels, EMAS guards against over-diagnosis and unnecessary testosterone prescribing driven by lab values alone.
This is something to take to a clinician. The Atlas can tell you what is known about emas in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The European Male Ageing Study was a large multicenter, population-based cohort of community-dwelling men aged 40-79 across eight European centers. Its pivotal 2010 NEJM paper by Frederick Wu and colleagues defined late-onset (age-related) hypogonadism syndromically: it required the co-occurrence of specific sexual symptoms AND low total and/or free testosterone, rather than a lab value alone. By insisting on three sexual symptoms (reduced morning erections, reduced sexual thoughts, erectile dysfunction) plus a testosterone threshold, EMAS produced a far more conservative and clinically meaningful definition and showed true late-onset hypogonadism is relatively uncommon.
The cohort that defined late-onset hypogonadism with actual symptom-hormone thresholds.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
EMAS correlated standardized symptom questionnaires with carefully measured morning testosterone across thousands of men to identify which symptoms genuinely track with low testosterone, then derived thresholds where symptoms become statistically more likely - turning 'low T' from a number into a syndrome.
Why EMAS deflated the 'low T epidemic'
EMAS showed that most non-specific symptoms blamed on 'low T' (fatigue, low mood, poor concentration) are NOT specifically linked to testosterone - only certain sexual symptoms are. It also demonstrated that much of the testosterone decline with age is driven by comorbidity and obesity rather than aging per se. This directly challenges the marketplace model of diagnosing hypogonadism from a single below-range lab value in a symptomatic-feeling man.
What people get wrong
Often saidLow T is an epidemic affecting most aging men
ActuallyBy EMAS's rigorous symptom-plus-biochemistry definition, true late-onset hypogonadism affected only about 2% of men 40-79 - far below the rates implied by lab-only screening.
Often saidFatigue and low mood reliably signal low testosterone
ActuallyEMAS found these non-sexual symptoms were NOT specifically associated with low testosterone; only certain sexual symptoms were.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
Published in NEJM in 2010 and led by Frederick Wu at the University of Manchester, EMAS became the basis for the syndromic definition of late-onset hypogonadism adopted by major guidelines, including the Endocrine Society. It is the principal scientific brake on the commercial 'low T' narrative.
- 2003-2005EMAS baseline recruitment across 8 European centers
- 2010Landmark syndromic LOH definition published in NEJM
- 2010sDefinition incorporated into Endocrine Society and other guidelines
What the trials could not show
Limits of the studies themselves, as distinct from limits of the treatment.
- Observational and cross-sectional for the core definition (no proof that treating EMAS-defined hypogonadism improves outcomes); European population may not generalize globally; thresholds are statistical constructs, not biological cliffs; single morning testosterone measurement has inherent variability.
What we do not know
- Do EMAS thresholds apply equally across ethnicities and non-European populations?
- Does treating EMAS-defined hypogonadism improve hard outcomes?
At a glance
- Design
- Multicenter, population-based observational cohort
- N
- ~3,369 analyzed (from ~3,400+ recruited)
- Ages
- 40-79, 8 European centers
- Key sexual symptoms
- Poor morning erection, low sexual thoughts, erectile dysfunction
- Threshold
- Total T <11 nmol/L (~320 ng/dL) AND free T <220 pmol/L
- Prevalence of LOH
- ~2% overall by the strict syndromic definition
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about EMAS. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Wu et al. (NEJM)2010
Defined late-onset hypogonadism as three sexual symptoms plus total T <11 nmol/L and free T <220 pmol/L; by this strict definition prevalence was only ~2%, rising with age and obesity
EMAS symptom-threshold analyses2010
Of many candidate symptoms, only the sexual symptoms were robustly and independently associated with low testosterone; physical and psychological symptoms were weaker and confounded